Rare Bleeding Disorders
Pharmacotherapies
Explore facts and recommendations for pharmacological treatments for rare bleeding disorders.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
Investigational Development of Mim8
Mimetic Optimization PDF
Mimetic Optimization PDF
Concizumab Mechanism of Action
This video discusses the mechanism of action of an investigational medicine, concizumab.
Emerging Non-Factor Therapies for Hemophilia
Mechanism of action for emerging therapies to treat hemophilia without using replacement coagulation factor.
Find more information
Find product information
Explore our portfolio of products for treating rare bleeding disorders, including prescribing information, safety data sheets and storage and stability information.
Continuing education
Explore accredited rare bleeding disorders education opportunities supported by Novo Nordisk and provided by third-party organizations.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
